Acknowledgement
We thank Yurim Kang, BS, and Seong Yeong Lee, BS, for their invaluable assistance with data collection and analysis.
References
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996 https://doi.org/10.1056/NEJMoa043330
- Treps L, Edmond S, Harford-Wright E, Galan-Moya EM, Schmitt A, Azzi S, et al. Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene 2016;35:2615-2623 https://doi.org/10.1038/onc.2015.317
- Dubois LG, Campanati L, Righy C, D'Andrea-Meira I, Spohr TC, Porto-Carreiro I, et al. Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci 2014;8:418
- Park JE, Kim HS, Jo Y, Yoo RE, Choi SH, Nam SJ, et al. Radiomics prognostication model in glioblastoma using diffusion- and perfusion-weighted MRI. Sci Rep 2020;10:4250
- Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr Med Imaging Rev 2007;3:91-107 https://doi.org/10.2174/157340507780619179
- Thomas AA, Arevalo-Perez J, Kaley T, Lyo J, Peck KK, Shi W, et al. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neurooncol 2015;125:183-190 https://doi.org/10.1007/s11060-015-1893-z
- Hwang I, Choi SH, Park CK, Kim TM, Park SH, Won JK, et al. Dynamic contrast-enhanced MR imaging of nonenhancing T2 high-signal-intensity lesions in baseline and posttreatment glioblastoma: temporal change and prognostic value. AJNR Am J Neuroradiol 2020;41:49-56 https://doi.org/10.3174/ajnr.A6323
- van Dijken BRJ, van Laar PJ, Smits M, Dankbaar JW, Enting RH, van der Hoorn A. Perfusion MRI in treatment evaluation of glioblastomas: clinical relevance of current and future techniques. J Magn Reson Imaging 2019;49:11-22 https://doi.org/10.1002/jmri.26306
- Yoo RE, Choi SH, Kim TM, Park CK, Park SH, Won JK, et al. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. Eur Radiol 2017;27:3156-3166 https://doi.org/10.1007/s00330-016-4692-9
- Kickingereder P, Burth S, Wick A, Gotz M, Eidel O, Schlemmer HP, et al. Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models. Radiology 2016;280:880-889 https://doi.org/10.1148/radiol.2016160845
- Zhou H, Vallieres M, Bai HX, Su C, Tang H, Oldridge D, et al. MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro Oncol 2017;19:862-870 https://doi.org/10.1093/neuonc/now256
- Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006
- Kim R, Choi SH, Yun TJ, Lee ST, Park CK, Kim TM, et al. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. Eur Radiol 2017;27:1176-1185 https://doi.org/10.1007/s00330-016-4464-6
- Kim JY, Yoon MJ, Park JE, Choi EJ, Lee J, Kim HS. Radiomics in peritumoral non-enhancing regions: fractional anisotropy and cerebral blood volume improve prediction of local progression and overall survival in patients with glioblastoma. Neuroradiology 2019;61:1261-1272 https://doi.org/10.1007/s00234-019-02255-4
- Leys C, Ley C, Klein O, Bernard P, Licata L. Detecting outliers: do not use standard deviation around the mean, use absolute deviation around the median. J Exp Soc Psychol 2013;49:764-766 https://doi.org/10.1016/j.jesp.2013.03.013
- Chollet F. Deep learning with python. New York: Manning, 2018
- Kim S, Shin J, Kim DY, Choi GH, Kim MJ, Choi JY. Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res 2019;25:3847-3855 https://doi.org/10.1158/1078-0432.CCR-18-2861
- Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2011;39:1-13 https://doi.org/10.18637/jss.v039.i05
- Liang C, Huang Y, He L, Chen X, Ma Z, Dong D, et al. The development and validation of a CT-based radiomics signature for the preoperative discrimination of stage I-II and stage III-IV colorectal cancer. Oncotarget 2016;7:31401-31412 https://doi.org/10.18632/oncotarget.8919
- Beig N, Bera K, Prasanna P, Antunes J, Correa R, Singh S, et al. Radiogenomic-based survival risk stratification of tumor habitat on Gd-T1w MRI is associated with biological processes in glioblastoma. Clin Cancer Res 2020;26:1866-1876 https://doi.org/10.1158/1078-0432.CCR-19-2556
- Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, et al. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp 2018;2:1-8 https://doi.org/10.1186/s41747-017-0034-1
- Rathore S, Akbari H, Doshi J, Shukla G, Rozycki M, Bilello M, et al. Radiomic signature of infiltration in peritumoral edema predicts subsequent recurrence in glioblastoma: implications for personalized radiotherapy planning. J Med Imaging (Bellingham) 2018;5:021219
- Schoenegger K, Oberndorfer S, Wuschitz B, Struhal W, Hainfellner J, Prayer D, et al. Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol 2009;16:874-878 https://doi.org/10.1111/j.1468-1331.2009.02613.x
- Choi KS, Choi SH, Jeong B. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network. Neuro Oncol 2019;21:1197-1209 https://doi.org/10.1093/neuonc/noz095
- Jung SC, Yeom JA, Kim JH, Ryoo I, Kim SC, Shin H, et al. Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 2014;35:1103-1110 https://doi.org/10.3174/ajnr.A3825
- Ulyte A, Katsaros VK, Liouta E, Stranjalis G, Boskos C, Papanikolaou N, et al. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients. Neuroradiology 2016;58:1197-1208 https://doi.org/10.1007/s00234-016-1741-7
- Trunk GV. A problem of dimensionality: a simple example. IEEE Trans Pattern Anal Mach Intell 1979;1:306-307 https://doi.org/10.1109/TPAMI.1979.4766926
- Verleysen M, Francois D. The curse of dimensionality in data mining and time series prediction. In: Cabestany J, Prieto A, Sandoval F, eds. Computational intelligence and bioinspired systems. Berlin, Heidelberg: Springer, 2005:758-770
- Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G; ESMO Guidelines Working Group. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:iii93-iii101 https://doi.org/10.1093/annonc/mdu050
- SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012;103:269-273 https://doi.org/10.1111/j.1349-7006.2011.02134.x
- Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014;16:81-91 https://doi.org/10.1093/neuonc/not159
- Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13:345
- Huang J, Yu J, Tu L, Huang N, Li H, Luo Y. Isocitrate dehydrogenase mutations in glioma: from basic discovery to therapeutics development. Front Oncol 2019;9:506
- Li ZC, Bai H, Sun Q, Zhao Y, Lv Y, Zhou J, et al. Multiregional radiomics profiling from multiparametric MRI: identifying an imaging predictor of IDH1 mutation status in glioblastoma. Cancer Med 2018;7:5999-6009 https://doi.org/10.1002/cam4.1863
- Hsieh KL, Chen CY, Lo CM. Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas. Oncotarget 2017;8:45888-45897 https://doi.org/10.18632/oncotarget.17585
- Tan Y, Mu W, Wang XC, Yang GQ, Gillies RJ, Zhang H. Improving survival prediction of high-grade glioma via machine learning techniques based on MRI radiomic, genetic and clinical risk factors. Eur J Radiol 2019;120:108609